XOMA Royalty successfully acquired 77.48% of HilleVax's outstanding shares through a tender offer at $1.95 per share plus a contingent value right, making HilleVax a wholly owned subsidiary.

HilleVax will be acquired by XOMA Royalty for $1.95 per share in cash, plus a contingent value right. The acquisition is expected to close in September 2025, with certain stockholders representing 22.9% of shares already supporting the merger.

HilleVax's stock plummeted after its sole clinical-stage vaccine candidate failed a phase 2b trial for norovirus-related acute gastroenteritis, leading to investor losses.

HilleVax's stock plummeted after its sole clinical-stage vaccine candidate failed a phase 2b trial for norovirus-related acute gastroenteritis, leading to investor losses.

HilleVax's (HLVX) short interest has risen 14.66% since its last report, with 20.02% of its shares sold short. This indicates increased bearish sentiment, as short selling is a strategy used to profit from a stock's decline.